CELZ - Creative Medical Greenstone team up to develop next-gen stem cell pipeline

Creative Medical Technology (NASDAQ:CELZ) signed an agreement with Greenstone Biosciences to develop a human induced pluripotent stem cell (iPSC) pipeline for its own ImmCelz platform. The project will be identified as iPScelz for future reference, Creative said in a June 15 press release. Creative noted that the next generation iPScelz pipeline for ImmCelz will enable large scale production and sustainability, while helping to reduce long term costs of manufacturing. "In combination with work continuing at the University of Miami, we believe that our ImmCelz platform has enormous potential to improve outcomes for patients across multiple indications, including Stroke, Type I Diabetes, Heart Disease, Liver Disease, and Kidney Disease," said Creative (CELZ)  President and CEO Timothy Warbington.

For further details see:

Creative Medical, Greenstone team up to develop next-gen stem cell pipeline